ASBM Hits Back At British Columbia Switching Scheme
Executive Summary
Originator-backed lobbying group the Alliance for Safe Biologic Medicines has raised concerns over a biosimilar switching policy recently unveiled by the Canadian province of British Columbia.
You may also be interested in...
Biosimilars Canada Boss Calls For Ontario Switching Policy
Biosimilars Canada president Jim Keon has urged the province of Ontario to follow other Canadian provinces by adopting a biosimilar switching policy for its public drug program, in order to cut costs on biologics and re-invest in the healthcare system.
Canadian Paper Pushes Back On Biosimilar Switching
A joint position statement published by originator-backed bodies the Canadian Association of Gastroenterology and Crohn’s and Colitis Canada has expressed caution over so-called ‘non-medical switching’ of IBD patients from brand biologics to biosimilars.
Brand-Backed Body Bemoans British Columbia’s Biosimilars Boost
A body supported by biologic originators has attacked British Columbia’s move to switch Crohn’s and colitis patient to infliximab biosimilars, even though the resulting savings will be invested in patient care.